Abstract: Dynamic shielding of cellular signals for an antenna of an unmanned aerial vehicle is disclosed. An example method may include receiving a navigation route for an unmanned aerial vehicle to execute during flight of the unmanned aerial vehicle and determining an orientation of a radio signal shield for an antenna of the unmanned aerial vehicle using ground level signal propagation information of radio signals for a network and the navigation route, wherein the radio signal shield prevents the radio signals from being received by the antenna from directions based on the orientation. The method may further include adjusting the radio signal shield using the orientation and communicating with a cellular base station of the network using the antenna.

Abstract: Maintaining network connectivity of aerial devices during unmanned flight is facilitated. An example method may include providing, to an access point of a radio access network (RAN) during flight of the unmanned aerial vehicle (UAV) on a flight route, channel allocation instructions for connecting the UAV to the radio access network via communication channels. The method may further include detecting an interference event associated with a portion of the flight route of the UAV during the flight. The method may further include adjusting, during the flight, the channel allocation instructions in response to detecting the interference event. The method may further include providing the adjusted channel allocation instructions to an access point of the radio access network during the flight.

Abstract: Disclosed are ophthalmic formulations which use complexes called L/H-HA, obtainable by subjecting at least two fractions of hyaluronic acids and/or other glycosaminoglycans with different molecular weights to an appropriate heat cycle.

Abstract: Disclosed are soluble polyelectrolyte complexes of polymeric biguanidine antimicrobial, such as polyhexamethylene biguanide or polyaminopropyl biguanide, with glycosaminoglycans, such as hyaluronic acid, chondroitin or chondroitin sulphate and derivatives thereof, and their use as active ingredients of pharmaceutical compositions or medical devices.

Abstract: Disclosed are ophthalmic formulations which use complexes called L/H-HA, obtainable by subjecting at least two fractions of hyaluronic acids and/or other glycosaminoglycans with different molecular weights to an appropriate heat cycle.

Abstract: Disclosed are novel formulations of oral tetraiodothyronine (T4), characterised by the formation in aqueous media of soluble, bioavailable micellar nanoaggregates.

Abstract: The present invention relates to the use of chondroitin as a transdermal carrier and slow-release system for active ingredients in pharmaceutical and cosmeceutical compositions.

Abstract: A cytomimetic formulation is provided comprising at least two of: (a) a fermented truffle extract; (b) a plurality of hyaluronic acids of different molecular weight, ranging from 50 KDa up to 2000 KDa; (c) an olive leaf extract in a mineral-containing water; and (d) a fermented grape must. The formulations mimic the skin cytoplasmic environment and create optimal conditions for cellular growth and skin rejuvenation. Methods of use and processes for manufacturing thereof are also provided.

Abstract: A cytomimetic formulation is provided comprising at least two of: (a) a fermented truffle extract; (b) a plurality of hyaluronic acids of different molecular weight, ranging from 50 KDa up to 2000 KDa; (c) an olive leaf extract in a mineral-containing water; and (d) a fermented grape must. The formulations mimic the skin cytoplasmic environment and create optimal conditions for cellular growth and skin rejuvenation. Methods of use and processes for manufacturing thereof are also provided.

Abstract: Describes cooperative hybrid complexes of hyaluronic acid, a simple and economical method for production thereof and use thereof in the area of medicine, cosmetics and food.

Abstract: The present invention relates to a downstream industrial method of purifying chondroitin sulphate obtained from animal cartilage, which produces a product fully compliant with the specifications required for the use of said compound in the pharmaceutical field.

Abstract: Chondroitin, a metabolic intermediate of chondroitin sulphate biosynthesis in mammals and other living organisms, possesses biological properties different from those of chondroitin sulphate, and can be advantageously used for applications in the pharmaceutical, nutraceutical, cosmeceutical and medical device fields. Chondroitin has biostimulating, anti-inflammatory and anti-microbial activity and can be used in the treatment of osteoarthritis, eye disorders, interstitial cystitis, lung disorders, inflammatory disorders in general, oncological disorders, peritoneal dialysis, tissue biorevitalisation and wound repair, as a skin filler, and as bioresorbable scaffolds.

Abstract: The present invention relates to the use of chondroitin as a transdermal carrier and slow-release system for active ingredients in pharmaceutical and cosmeceutical compositions.

Abstract: Disclosed are pharmaceutical formulations and their use for the treatment of retinitis pigmentosa, comprising tetra- or pentapeptides.

Abstract: Disclosed are pharmaceutical formulations for the treatment of diabetes, comprising a combination of insulin with tetra- or pentapeptides having an anti-inflammatory and antiangiogenic activity.

Abstract: Disclosed are novel formulations of oral tetraiodothyronine (T4), characterised by the formation in aqueous media of soluble, bioavailable micellar nanoaggregates.

Abstract: Disclosed are ophthalmic formulations which use complexes called L/H-HA, obtainable by subjecting at least two fractions of hyaluronic acids and/or other glycosaminoglycans with different molecular weights to an appropriate heat cycle.

Abstract: A cytomimetic formulation is provided comprising at least two of: (a) a fermented truffle extract; (b) a plurality of hyaluronic acids of different molecular weight, ranging from 50 KDa up to 2000 KDa; (c) an olive leaf extract in a mineral-containing water; and (d) a fermented grape must. The formulations mimic the skin cytoplasmic environment and create optimal conditions for cellular growth and skin rejuvenation. Methods of use and processes for manufacturing thereof are also provided.

Abstract: Disclosed are novel formulations of oral tetraiodothyronine (T4), characterised by the formation in aqueous media of soluble, bioavailable micellar nanoaggregates.

Abstract: The present invention relates to a downstream industrial method of purifying chondroitin sulphate obtained from animal cartilage, which produces a product fully compliant with the specifications required for the use of said compound in the pharmaceutical field.